Chemical Data Sample Clauses

Chemical Data. ‌ Chemical data is reviewed as described in Section 4.6.1. through Section 4.6.4 and then evaluated to identify TCE concentration trends for ▇▇▇▇▇ in the monitoring network. The results of periodic and long-term contaminant monitoring are tabulated and provided to stakeholders for review semiannually, as described in Section 4.5. These tables are designed to facilitate observation of trends over time. Graphs showing changes over time also are developed. TCE mass capture from system operation are calculated based on EW sample data and flow rates. Statistical analyses may be used to compare data sets or to assess trends over time, including calculation of summary statistics and determining the significance of trends. These statistical techniques may include comparative analyses, multivariate comparison, trend analysis, linear regression, variable correlation, and multivariate correlation. These analyses often are problem specific and may or may not be relevant to addressing the objectives of NWGPS effectiveness monitoring. Regardless, the data density from the monitoring network is sufficiently robust to provide the data necessary, should a statistical analysis be required. Operational adjustments to maximize the efficiency of the remedial systems may be recommended based partially on a review of influent concentrations and mass capture results. The long-term monitoring data will be used to assess potential issues of long-term plume fate that may be related to potential long-term optimization efforts. As part of data evaluation, the monitoring network will be reevaluated periodically to ensure that the objectives of the effectiveness monitoring program are being obtained. Over time, changes in plume configuration or flow trajectories may require modification to the MW network to provide appropriate coverage.
View SourceView Similar (2)
Chemical Data. Chemical data will be evaluated to identify TCE and Tc-99 trends for ▇▇▇▇▇ in the monitoring network. The results of periodic and long-term contaminant monitoring will be tabulated and provided to stakeholders for review semiannually, as described in Section 4.5. These tables are designed to facilitate observation of trends over time. Graphs showing changes over time also are developed, as needed. TCE mass capture from system operation is calculated based on EW samples and flow rates. Statistical analyses may be used to compare data sets or to assess trends over time, including calculation of summary statistics and determining the significance of trends. These statistical techniques may include comparative analyses, multivariate comparison, trend analysis, linear regression, variable correlation, and multivariate correlation. These analyses often are problem specific and may or may not be relevant to addressing the objectives of NEPCS effectiveness monitoring. Regardless, the data density from the proposed monitoring network is sufficiently robust to provide the data necessary, should a statistical analysis be required. Operational adjustments to maximize the efficiency of the remedial systems may be recommended based partially on a review of influent concentrations and mass capture results. The long-term monitoring data will be used to assess potential issues of long-term plume fate that may be related to potential long-term optimization efforts. As part of data evaluation, the monitoring network will be reevaluated periodically to ensure that the objectives of the effectiveness monitoring program are being obtained.
View Source

Related to Chemical Data

  • Technical Data For the purpose of this Agreement, "TECHNICAL DATA" shall mean all information of the Company in written, graphic or tangible form relating to any and all products which are developed, formulated and/or manufactured by the Company, as such information exists as of the Effective Date or is developed by the Company during the term hereof.

  • Sensitive data Where the transfer involves personal data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, genetic data, or biometric data for the purpose of uniquely identifying a natural person, data concerning health or a person’s sex life or sexual orientation, or data relating to criminal convictions and offences (hereinafter ‘sensitive data’), the data importer shall apply the specific restrictions and/or additional safeguards described in Annex I.B.

  • Confidential Data A. UTK shall not divulge to others, any trade secret or confidential information, knowledge, or data concerning or pertaining to the business and affairs of MGCN, obtained by UTK as a result of its engagement hereunder, unless authorized, in writing by MGCN. UTK represents and warrants that it has established appropriate internal procedures for protecting the trade secrets and confidential information of, MGCN including, without limitation, restrictions on disclosure of such information to employees and other persons who may be engaged in such information to employees and other persons who may be engaged in rendering services to any person, firm or entity which may be a competitor of. B. MGCN shall not divulge to others, any trade secret or confidential information, knowledge, or data concerning or pertaining to the business and affairs of UTK obtained as a result of its engagement hereunder, unless authorized, in writing, by UTK. C. UTK shall not be required in the performance of its duties to divulge to MGCN, or any officer, director, agent or employee of MGCN, any secret or confidential information, knowledge, or data concerning any other person, firm or entity (including, but not limited to, any such person, firm or entity which may be a competitor or potential competitor of) which UTK may have or be able to obtain other than as a result of the relationship established by this Agreement.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • Industry Data The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.